Avantor (AVTR) Projected to Post Earnings on Wednesday

Avantor (NYSE:AVTR) is projected to issue its Q4 2025 results before the market opens on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.21 per share and revenue of $1.6359 billion for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 8:00 AM ET.

Avantor Price Performance

Shares of NYSE:AVTR opened at $10.84 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.96 and a current ratio of 1.49. The firm has a market cap of $7.39 billion, a price-to-earnings ratio of -83.41, a price-to-earnings-growth ratio of 3.84 and a beta of 0.94. The business has a 50-day simple moving average of $11.55 and a two-hundred day simple moving average of $12.38. Avantor has a fifty-two week low of $10.62 and a fifty-two week high of $22.44.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. UBS Group set a $12.00 price objective on shares of Avantor in a report on Thursday, October 30th. Evercore ISI set a $12.00 target price on shares of Avantor and gave the stock an “in-line” rating in a research report on Monday, January 5th. Raymond James Financial cut Avantor from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 4th. Bank of America downgraded Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price target on the stock. in a research note on Monday, December 15th. Finally, Robert W. Baird upped their price objective on Avantor from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Three analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $13.60.

Insider Buying and Selling

In related news, Director Sanjeev K. Mehra bought 350,000 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were bought at an average cost of $11.09 per share, for a total transaction of $3,881,500.00. Following the completion of the transaction, the director owned 350,000 shares of the company’s stock, valued at approximately $3,881,500. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its holdings in Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after acquiring an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC bought a new stake in Avantor during the 2nd quarter valued at approximately $32,000. Osaic Holdings Inc. lifted its holdings in Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Avantor by 28.1% during the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,123 shares of the company’s stock valued at $49,000 after buying an additional 905 shares in the last quarter. Finally, Danske Bank A S bought a new stake in shares of Avantor during the third quarter valued at approximately $85,000. Institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.